Sanofi
Novel 2,3-Dihydro-1h-imidazo{1,2-a}pyrimidin-5-one and this 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one Derivatives Comprising a Substituted Morpholine, Preparation Thereof and Pharmaceutical Use Thereof

Abstract:

The invention relates to the novel products of formula (I): ##STR00001## with p, q=0, 1 or 2; R1=phenyl, pyridyl; --(CH.sub.2).sub.m--Ra; alkylene; cycloalkyl; heterocycloalkyl; alkyl; --SO.sub.2--Rb; --CO--Re; m=1 or 2; Ra=aryl, heteroaryl, --CO-cycloalkyl, --CO-heterocycloalkyl, --CO--Rb, --C(Rb).dbd.N--ORc, --CO.sub.2Rd, --CONRxRy; Rb=alkyl, aryl, heteroaryl; Rc=H, alkyl; Rd=alkyl, cycloalkyl; Re=alkyl, cycloalkyl, aryl, heteroaryl; NRxRy with Rx,Ry=H, alkyl, cycloalkyl, alkoxy, phenyl, or form with N a ring with optionally O, N; R2, R3=H, alkyl, CF.sub.3, or form with C a ring with optionally O, S and N; R4=H, F, Cl, CH.sub.3 or CN; the morpholine is substituted with Me, and optionally substituted with F, OH; or is ##STR00002## and the isomer of configuration R,R ##STR00003## these products being in all the isomer forms and the salts, as medicaments, in particular as anticancer medicaments.